Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 27;45(7):160.
doi: 10.1007/s00296-025-05910-7.

Sex- and gender-related differences in systemic lupus erythematosus: a scoping review

Katinka Albrecht  1 , Wiebke Troll  2 , Johanna Callhoff  3 , Anja Strangfeld  3   4 , Sarah Ohrndorf #  4   5   6 , Johanna Mucke #  7   8
Affiliations

Sex- and gender-related differences in systemic lupus erythematosus: a scoping review

Katinka Albrecht et al. Rheumatol Int. .

Abstract

A scoping review was conducted to compile evidence on sex-specific differences in systemic lupus erythematosus (SLE) with focus on autoantibodies, organ manifestation, damage, treatment and patient-reported outcomes (PROs). Systematic searches in PubMed and Cochrane were performed including meta-analyses, observational studies and clinical trials from 01/2015 to 11/2024. Studies of adults with SLE reporting outcomes by sex were eligible. The research protocol is registered in the Registry for Scoping Reviews (OSF, https://osf.io/gfbs9 ). From 373 screened articles, 81 publications were included. Studies comprised differences in autoantibodies (n = 13), damage (n = 40), organ involvement (n = 27), treatment (n = 14), and PROs (n = 6). Twenty studies compared proportions of outcomes by sex with patient numbers ranging from 98 to 11,943. The female/male ratio was between 4:1 and 11:1. The review found a higher age at onset in men and a higher proportion of positive lupus anticoagulant, nephritis, serositis, antiphospholipid syndrome, greater renal and cardiovascular damage and severe infections. SLE in women more often presented with Ro/SSA autoantibodies, alopecia, photosensitivity, Raynaud, and osteoporosis. Some studies showed more frequent cyclophosphamide and less frequent antimalarials in men. Little evidence indicated more frequent non-adherence with azathioprine and mycophenolate in women. Limited evidence was available for PROs. This review confirms significant sex differences in SLE, with men showing later onset, more severe organ damage, and distinct autoantibody and treatment patterns, while women more often present with Ro/SSA autoantibodies, photosensitivity, and osteoporosis. Evidence on patient-reported outcomes remains limited, highlighting the need for further research to guide sex-specific management.

Keywords: Antirheumatic agents; Gender differences; Patient-reported outcomes; Sex differences; Systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: KA declares no competing interests. WT has received speaker honoraria from GSK, consultant fees from GSK, Roche and Pfizer. JM has received consultant fees from AbbVie, AstraZeneca, BMS, GlaxoSmithKline, Novartis, Lilly, UCB, Ostuka; Speakers fees from AbbVie, AstraZeneca, Bristol Myers Squibb, GSK, Janssen-Cilag, Lilly, Novartis, Otsuka, grants/research support from GlaxoSmithKline, Sanofi Aventis and travel grants from AbbVie. SO has received speakers fee from AbbVie, Alfasigma, Amgen, AstraZeneca, BMS, Johnson&Johnson, Lilly, Novartis, and UCB; consultant fees from Amgen, Johnson&Johnson, Mylan, Novartis and UCB and Grants/research support from GSK and Novartis. AS has received speaker fees from AbbVie, Galapagos/Alfasigma, Janssen, Lilly, Pfizer, Takeda and UCB. JC has received speaker fees from Janssen, Pfizer, Idorsia. Ethical approval: The scoping review is based on previously conducted studies and does not contain any new studies with human participants or animals. Patient consent for publication: Not required.

Similar articles

See all similar articles

References

    1. Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W (2017) The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford) 56(11):1945–1961 - PubMed
    1. Mahmood SB, Aziz M, Malepati D et al (2024) Evaluating sex differences in the characteristics and outcomes of lupus nephritis: A systematic review and Meta-Analysis. Glomerular Dis 4(1):19–32 - PMC - PubMed
    1. Lee MH, Koh JWH, Ng CH et al (2022) A meta-analysis of clinical manifestations in Asian systemic lupus erythematous: the effects of ancestry, ethnicity and gender. Semin Arthritis Rheum 52:151932 - PubMed
    1. Boodhoo KD, Liu S, Zuo X (2016) Impact of sex disparities on the clinical manifestations in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Med (Baltim) 95(29):e4272 - PMC - PubMed
    1. Choi CB, Liang MH, Bae SC (2016) Progress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activity. Arthritis Res Ther 18:1 - PMC - PubMed

Publication types